Literature DB >> 33280015

Lupus nephritis: clinical presentations and outcomes in the 21st century.

Michela Gasparotto1, Mariele Gatto1, Valentina Binda2, Andrea Doria1, Gabriella Moroni2.   

Abstract

Lupus nephritis (LN) is a frequent and severe manifestation of SLE. Along the decades, the epidemiology of LN and its clinical presentation have been changing. However, even though retrospective cohort studies report a decreased mortality rate and an improvement in the disease prognosis, the percentage of patients progressing into end stage renal disease (ESRD) keeps steady despite the improvements in therapeutic strategies. Current in-use medications have been available for decades now, yet over the years, regimens for optimizing their efficacy and minimizing toxicity have been developed. Therapeutic research is now moving towards the direction of precision medicine and several new drugs, targeting selectively different pathogenetic pathways, are currently under evaluation with promising results. In this review, we address the main changes and persistent unmet needs in LN management throughout the past decades, with a focus on prognosis and upcoming treatments.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Entities:  

Keywords:  B cells; calcineurin inhibitors; classification; lupus nephritis; prognosis; renal biopsy; risk factors

Year:  2020        PMID: 33280015     DOI: 10.1093/rheumatology/keaa381

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  26 in total

1.  Pr-AKI: Acute Kidney Injury in Pregnancy - Etiology, Diagnostic Workup, Management.

Authors:  Florian G Scurt; Ronnie Morgenroth; Katrin Bose; Peter R Mertens; Christos Chatzikyrkou
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-03-03       Impact factor: 2.915

2.  Spectrum of Morphological and Immunofluorescence Patterns in Lupus Nephritis: A Single Institutional Study.

Authors:  Saira Javeed; Safana Sadaf; Saima Batool; Ayma Batool; Zubaria Rafique; Akhtar S Chughtai
Journal:  Cureus       Date:  2022-05-26

3.  1,25-dihydroxyvitamin D3 ameliorates lupus nephritis through inhibiting the NF-κB and MAPK signalling pathways in MRL/lpr mice.

Authors:  Xuewei Li; Jie Liu; Yingzhe Zhao; Ning Xu; E Lv; Chunzeng Ci; Xiangling Li
Journal:  BMC Nephrol       Date:  2022-07-08       Impact factor: 2.585

4.  Analysis of the safety and efficacy of tacrolimus combined with glucocorticoid in the treatment of lupus nephritis.

Authors:  Lu Li; Yong Du; Juan Ji; Ying Gao; Xiao-Qiang Shi
Journal:  Pak J Med Sci       Date:  2022 May-Jun       Impact factor: 2.340

5.  Potential Small Molecules for Therapy of Lupus Nephritis Based on Genetic Effect and Immune Infiltration.

Authors:  Jianbo Qing; Wenzhu Song; Lingling Tian; Sonia Biju Samuel; Yafeng Li
Journal:  Biomed Res Int       Date:  2022-04-23       Impact factor: 3.246

6.  Umbilical Cord Mesenchymal Stem Cells Ameliorate Kidney Injury in MRL/Ipr Mice Through the TGF-β1 Pathway.

Authors:  Chunkai Huang; Mingyao Meng; Shuo Li; Shiyuan Liu; Lin Li; Yanjun Su; Hui Gao; Shan He; Yiyi Zhao; Min Zhang; Zongliu Hou; Wenju Wang; Xiaodan Wang
Journal:  Front Cell Dev Biol       Date:  2022-04-05

7.  Class II lupus nephritis with podocyte injury in imiquimod-induced lupus-prone mice.

Authors:  Atsuko Murai; Masaki Yamazaki; Kaori Nishihara; Aki Kito; Sohei Oyama; Naoshi Horiba; Atsuhiko Kato
Journal:  Histol Histopathol       Date:  2022-03-17       Impact factor: 2.130

Review 8.  Immune-Related Urine Biomarkers for the Diagnosis of Lupus Nephritis.

Authors:  María Morell; Francisco Pérez-Cózar; Concepción Marañón
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

9.  Lupus in the 21st century.

Authors:  Chiara Tani
Journal:  Rheumatology (Oxford)       Date:  2020-12-05       Impact factor: 7.580

10.  Comprehensive Analysis of Clinical Trials Registration for Lupus Nephritis Therapy on ClinicalTrials.gov.

Authors:  Yanfang Gao; Yuhan Wang; Rongshan Li; Xiaoshuang Zhou
Journal:  Front Med (Lausanne)       Date:  2021-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.